Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. cut its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) by 39.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 2,383,029 shares of the company’s stock after selling 1,538,213 shares during the period. Baillie Gifford & Co.’s holdings in Vir Biotechnology were worth $17,849,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Innealta Capital LLC acquired a new stake in shares of Vir Biotechnology in the second quarter worth approximately $32,000. Blue Trust Inc. raised its stake in Vir Biotechnology by 143.5% during the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock worth $30,000 after purchasing an additional 2,351 shares during the period. nVerses Capital LLC acquired a new position in shares of Vir Biotechnology in the 3rd quarter valued at $56,000. Magnetar Financial LLC purchased a new stake in shares of Vir Biotechnology during the 2nd quarter valued at $95,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Vir Biotechnology during the 1st quarter worth $119,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Price Performance

Vir Biotechnology stock opened at $9.25 on Wednesday. Vir Biotechnology, Inc. has a one year low of $7.12 and a one year high of $13.09. The stock’s 50 day moving average price is $7.92 and its 200 day moving average price is $8.95.

Vir Biotechnology (NASDAQ:VIR) last announced its earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.51). The firm had revenue of $2.38 million during the quarter, compared to analysts’ expectations of $5.54 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. Vir Biotechnology’s revenue for the quarter was down 9.8% compared to the same quarter last year. During the same quarter last year, the company posted ($1.22) earnings per share. As a group, research analysts predict that Vir Biotechnology, Inc. will post -3.86 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on VIR shares. Needham & Company LLC reissued a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a research report on Friday, November 1st. Barclays reduced their price target on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research report on Monday, November 4th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $36.40.

Insider Buying and Selling at Vir Biotechnology

In other news, Director Janet Napolitano sold 12,190 shares of Vir Biotechnology stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $7.80, for a total transaction of $95,082.00. Following the sale, the director now directly owns 11,616 shares of the company’s stock, valued at approximately $90,604.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 15,940 shares of company stock valued at $127,410 in the last ninety days. Insiders own 15.60% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).